Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GenSight Undeterred By Gene Therapy’s Placebo Puzzle

Executive Summary

Phase III success at 96 weeks sets up GenSight blindness therapy for EU filing, but puzzle of placebo arm benefits remain

You may also be interested in...



Mystery Solved? GenSight’s Gene Therapy Does Move Between Eyes

Company boosted by animal study which helps answer riddle of improvement in untreated eye.

Novartis Prepares for UK Luxturna Rollout After Rapid NICE OK

Novartis/Spark’s gene therapy Luxturna has been OKd for NHS use by NICE in record time thanks to early engagement and close collaboration between the two parties. 

GenSight Sees Positives In Pivotal RESCUE Trial, Despite Missing Primary Endpoint

The company's gene therapy didn't hit the primary endpoints in either of its two Phase III studies in a severe genetic retinal disease reported so far, but a third trial designed through a special protocol assessment with the US FDA is ongoing.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel